Collaboration partner Gilead Sciences provided $20m as the cancer therapy researcher extended its overall equity funding to $165m.
US-based oncology drug research provider Tango Therapeutics completed a $50m equity financing round on Monday featuring $20m from biopharmaceutical company Gilead Sciences through a partnership agreement.
Healthcare investment firm Casdin Capital led the round, which included investment manager Cormorant Asset Management and Boxer Capital, a subsidiary of investment group Tavistock Group.
Tango is studying the genetic drivers of cancer to discover targets for drugs that will destroy cancerous cells through synthetic lethality, preventing them from evading the body’s immune system…
